GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Capital Expenditure

Satellos Bioscience (TSX:MSCL) Capital Expenditure : C$-0.01 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Satellos Bioscience's cash flow for capital expenditures for the three months ended in Dec. 2024 was C$0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was C$-0.01 Mil.

Satellos Bioscience Capital Expenditure Historical Data

The historical data trend for Satellos Bioscience's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Capital Expenditure Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
- -0.01 - -0.02 -0.01

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Satellos Bioscience Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Satellos Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Capital Expenditure
Comparable Companies
TSXV:ARCH TSX:MDNA XCNQ:GLAB TSX:ONC TSXV:COV XCNQ:ONCO TSXV:MIR TSX:SVA TSXV:NRX TSXV:SHRX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
MSCLF:USA 0ITA:Germany
Address
200 Bay Street, Suite 2800, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience Headlines

No Headlines